Frontiers in Pharmacology · Oct 30, 2026

Betaine for Diabetes: Preclinical Promise, Conflicting Human Evidence, Gut Microbiota‑TMAO Confounder, and Pathways Toward Rigorous Clinical Translation

By Keping Xie

Betaine (N,N,N-trimethylglycine), abundant in sugar beets, spinach and quinoa, acts as mammalian cellular osmoprotectant and core one-carbon methyl donor. This translational review synthesizes epidemiological, preclinical and clinical evidence on betaine-diabetes interactions, with strict stratification of evidence tiers including cell assays, rodent models, human observational cohorts and randomized controlled trials (RCTs). Observational data show inverse correlations between circulating betaine and incident type 2 diabetes (T2D), whereas meta-analyses find no consistent protective effect of dietary betaine intake, confounded by lifestyle bias and diabetes-related renal reverse causation. In vitro and rodent models confirm betaine alleviates insulin resistance through coordinated IRS1-AKT, AMPK, anti-oxidative and ER stress pathways, plus upregulated FGF21 and enhanced mitochondrial function. Preclinical rodent data demonstrate betaine's protective effects against diabetic micro-and macrovascular complications (nephropathy, retinopathy, neuropathy, cardiovascular damage), yet no human RCTs validate these organ benefits. Gut microbes convert betaine to TMAO, a metabolite associated with higher cardiometabolic and T2D risk, leading to variable individual responses to oral supplementation. The single small, short prediabetes RCT available to date yielded no robust glycemic benefits but raised plasma TMAO, precluding the routine clinical use of supplemental betaine for management of T2D or gestational diabetes mellitus (GDM). Future work demands large long-term stratified human trials, microbiota-targeted co-interventions and novel betaine derivatives to separate therapeutic effects from microbial TMA generation.

The paperJournal siteInterventions

AgingResearch.News